J&J hands over $3.1M for .Baby; Pfizer announces promising Phase III data for Lyrica;

> Johnson & Johnson ($JNJ) shelled out $3.1 million in an auction for .Baby, beating out bidders such as Google ($GOOG). Story

> Pfizer ($PFE) reported promising Phase III clinical results for its nerve-pain treatment Lyrica (pregabalin). More (sub. req.)

> The FDA's Office of Prescription Drug Promotion is cracking down on one of Sunovion's print ads for seizure med Aptiom. Story (reg. req.)

> Starting in January, the Indian government will ban pharma companies from handing out freebies to doctors. More

> Apotex submitted an application to the FDA for a copycat version of Amgen's ($AMGN) $3.5 billion blockbuster Neulasta. Story (req. req.)

And Finally… The pharma industry is funneling money into veterinary education, with the world's leading animal drugmaker, Zoetis ($ZTS), awarding $3.6 million in scholarships over the past 5 years. More

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.